Foresite Capital Management IV as of Sept. 30, 2021
Portfolio Holdings for Foresite Capital Management IV
Foresite Capital Management IV holds 12 positions in its portfolio as reported in the September 2021 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Kinnate Biopharma | 32.8 | $223M | 9.7M | 23.02 | |
| Lyell Immunopharma (LYEL) | 28.9 | $197M | 13M | 14.80 | |
| Aclaris Therapeutics (ACRS) | 9.0 | $61M | 3.4M | 18.00 | |
| Pharvaris N V (PHVS) | 8.5 | $58M | 3.3M | 17.73 | |
| Quantum-Si Incorporated Com Cl A (QSI) | 5.5 | $37M | 4.5M | 8.34 | |
| Nurix Therapeutics (NRIX) | 5.3 | $36M | 1.2M | 29.96 | |
| Kura Oncology (KURA) | 5.1 | $35M | 1.8M | 18.73 | |
| Cue Health (HLTHQ) | 1.7 | $12M | 1.0M | 11.81 | |
| Olema Pharmaceuticals (OLMA) | 1.4 | $9.4M | 342k | 27.56 | |
| Cymabay Therapeutics | 1.0 | $6.5M | 1.8M | 3.65 | |
| Tempest Therapeutics (TPST) | 0.4 | $2.8M | 190k | 14.47 | |
| Decibel Therapeutics | 0.3 | $2.3M | 298k | 7.71 |
